Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus
AA Khan, A Morrison, DA Hanley… - Journal of Bone and …, 2015 - Wiley Online Library
This work provides a systematic review of the literature from January 2003 to April 2014
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of …
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of …
Managing osteoporosis in patients on long‐term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research
RA Adler, G El‐Hajj Fuleihan, DC Bauer… - Journal of Bone and …, 2016 - academic.oup.com
Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This
ASBMR report provides guidance on BP therapy duration with a risk‐benefit perspective …
ASBMR report provides guidance on BP therapy duration with a risk‐benefit perspective …
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the …
JW Hellstein, RA Adler, B Edwards… - The Journal of the …, 2011 - Elsevier
Background This narrative review of osteonecrosis of the jaw in patients with low bone mass
receiving treatment with antiresorptive agents is based on an appraisal of the literature by an …
receiving treatment with antiresorptive agents is based on an appraisal of the literature by an …
Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS
AD Anastasilakis, J Pepe, N Napoli… - The Journal of …, 2022 - academic.oup.com
Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …
Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015
Osteonecrosis of the jaw (ONJ) has been associated with the use of aminobisphosphonates
and denosumab. The vast majority (> 90%) of cases occur in the oncology patient …
and denosumab. The vast majority (> 90%) of cases occur in the oncology patient …
Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents
Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and
denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related …
denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related …
Antiresorptives and osteonecrosis of the jaw
J Yamashita, LK McCauley - Journal of Evidence Based Dental Practice, 2012 - Elsevier
Osteonecrosis of the jaw (ONJ) is an uncommon condition noted to occur in patients who are
receiving osteoclast-targeted antiresorptive therapy. The incidence of ONJ in patients taking …
receiving osteoclast-targeted antiresorptive therapy. The incidence of ONJ in patients taking …
Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and …
Bisphosphonates are the most widely prescribed drugs for the treatment of osteoporosis,
and are also used in malignant bone metastases, multiple myeloma, and Paget's disease …
and are also used in malignant bone metastases, multiple myeloma, and Paget's disease …
What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta‐analysis
Objective A systematic review and meta‐analysis are carried out to assess the scientific
evidence that bisphosphonate therapy can decrease the success rate of dental implants …
evidence that bisphosphonate therapy can decrease the success rate of dental implants …
Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws
Purpose Bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) is a side effect of
BP therapy. Dental implants are believed to be a risk factor for developing BRONJ. In the …
BP therapy. Dental implants are believed to be a risk factor for developing BRONJ. In the …